People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
NICE International has helped Egypt take a crucial step towards a fairer, more efficient healthcare system.
An end of year summary from our chief executive, Dr Sam Roberts.
Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS.
Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in the NHS, and how you can get involved in suggesting future updates.
